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Trichinella spiralis, as well as its muscle larvae excretory–secretory products (ES L1), 
given either alone or via dendritic cells (DCs), induce a tolerogenic immune micro-
environment in inbred rodents and successfully ameliorate experimental autoimmune 
encephalomyelitis. ES L1 directs the immunological balance away from T helper (Th)1, 
toward Th2 and regulatory responses by modulating DCs phenotype. The ultimate goal 
of our work is to find out if it is possible to translate knowledge obtained in animal model 
to humans and to generate human tolerogenic DCs suitable for therapy of autoimmune 
diseases through stimulation with ES L1. Here, the impact of ES L1 on the activation of 
human monocyte-derived DCs is explored for the first time. Under the influence of ES 
L1, DCs acquired tolerogenic (semi-matured) phenotype, characterized by low expres-
sion of HLA-DR, CD83, and CD86 as well as moderate expression of CD40, along with 
the unchanged production of interleukin (IL)-12 and elevated production of IL-10 and 
transforming growth factor (TGF)-β, compared to controls. The interaction with DCs 
involved toll-like receptors (TLR) 2 and 4, and this interaction was mainly responsible 
for the phenotypic and functional properties of ES L1-treated DCs. Importantly, ES L1 
potentiated Th2 polarizing capacity of DCs, and impaired their allo-stimulatory and Th1/
Th17 polarizing properties. Moreover, ES L1-treated DCs promoted the expansion of 
IL-10- and TGF-β- producing CD4+CD25hiFoxp3hi T cells in indolamine 2, 3 dioxygen-
ase (IDO)-1-dependent manner and increased the suppressive potential of the primed 
T cell population. ES L1-treated DCs retained the tolerogenic properties, even after the 
challenge with different pro-inflammatory stimuli, including those acting via TLR3 and, 
especially TLR4. These results suggest that the induction of tolerogenic properties of 
DCs through stimulation with ES L1 could represent an innovative approach for the 
preparation of tolerogenic DC for treatment of inflammatory and autoimmune disorders.
Keywords: Trichinella spiralis, excretory–secretory products, dendritic cells, tolerance, immunomodulation, toll-
like receptors
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inTrODUcTiOn
One of the permanent challenges in immunology is overcoming 
the rising problem of losing the delicate balance, provided by 
the innate immunity, reflected in responding to foreign antigens 
while remaining tolerant to self-antigens. If this balance is altered 
due to an increased inflammatory response and diminished 
tolerance, it can result in autoimmune diseases such as type I 
diabetes, multiple sclerosis, rheumatoid arthritis, and inflamma-
tory bowel disease (1). Currently available treatments for those 
diseases do not provide cure or a long-term remission. They 
usually include immunosuppressive drugs or biological agents 
which slow down the disease progress but can cause serious 
adverse effects (2). Given that available therapy cannot restore 
self-tolerance and provides only temporary remission, efforts are 
being made in order to develop new therapeutic approaches that 
would enable the restoration of tolerogenic immune response 
and silencing of autoimmune processes (3, 4). Dendritic cells 
(DCs), key antigen-presenting cells, possess the capacity for a 
fine tuning of the immune response and represent a good can-
didate as an immunotherapeutic tool (5–8), since their plasticity 
provides the opportunity to reverse the autoimmune process by 
mediating restoration of self-tolerance (9).
From the beginning of twenty-first century, a number of results 
obtained in animal model systems provided evidence that DCs 
could be treated in a way to acquire tolerogenic properties and 
that such DCs have a potential to mitigate autoimmune diseases 
like autoimmune diabetes (10, 11), collagen-induced arthritis 
(12, 13), experimental autoimmune encephalomyelitis (EAE) 
(14–16), experimental autoimmune myasthenia gravis (17, 18), 
and experimental autoimmune uveoretinitis (19, 20). It has 
been demonstrated that the tolerogenic status of DCs depends 
on the applied stimuli and maturation conditions. The doctrine 
that, by default, immature DCs are considered tolerogenic while 
mature DCs are immunogenic and induce effector responses 
(21) has been modified by the fact that even mature DCs could 
have tolerogenic properties (1, 22). Nevertheless, tolerogenic 
phenotype of DCs usually refers to semi-matured cells with low 
to intermediate expression of MHC II, as well as co-stimulatory 
molecules CD80, CD86, and CD40, with elevated production of 
interleukin (IL)-10 but decreased production of IL-12 (23–25). 
Different agents proved to be potent inducers of tolerogenic DCs 
phenotype. Among them are vitamin D3 (26, 27), corticosteroids 
(28), rapamycin (29), IL-10 (30, 31), or other cytokines (32). The 
observed phenomenon that tolerogenic DCs could modulate the 
course of autoimmune disease in terms of reducing the clinical 
signs and the severity of the disease, directed research from 
animal model system toward human DCs. Some of these inves-
tigations, that showed success in vitro, have turned into phase I 
clinical trials over time (5, 33). Nevertheless, a search for agents 
able to induce stable tolerogenic DCs is an ongoing story.
It is well known that parasite antigens have the potential 
to modulate the host immune response via DCs by inducing 
T helper (Th)2 and regulatory response while simultaneously 
inhibiting Th1 and Th17 response (34) and some of the inves-
tigated parasitic antigens showed the capacity to induce tolero-
genic DCs phenotype (35, 36). Still, the results considering the 
impact of parasitic products on human DCs, their tolerogenic 
properties and the potential of these tolerogenic DCs to modu-
late the immune response, as well as the mechanisms employed 
in this phenomenon, are scarce. Potential candidates for the 
induction of tolerogenic DCs are excretory–secretory (ES L1) 
antigens of Trichinella spiralis muscle larvae. ES L1 antigens are a 
complex mixture of molecules, released by this parasite into the 
circulation during the chronic phase of the infection, which can 
activate regulatory network elements as guardians of homeosta-
sis. Through the action of these products, mediated mainly by 
DCs, the parasite suppresses the host immune response against 
itself in order to survive, but it also mitigates the unwanted 
immune responses like those to autoantigens and allergens (37). 
Several studies, including our own (38), preformed in mouse 
model system, showed that ES L1 antigens of T. spiralis muscle 
larvae, or its components (39) possess the ability to induce the 
semi-matured DCs, which are able to induce the expansion 
of regulatory T  cells (Tregs) in  vitro. Our work using the rat 
model system also demonstrated that upon treatment with ES 
L1 antigens, DCs acquire semi-mature status and an increased 
capacity to induce Th2 and regulatory immune response both 
in  vitro and in  vivo (40). Also, ES L1-treated DCs, if applied 
prophylactically, showed considerable ability to modulate the 
outcome of EAE in Dark Agouti rats by activating and maintain-
ing anti-inflammatory and regulatory immune response while 
alleviating pro-inflammatory response (16). This was reflected 
in the enhanced production of IL-4, IL-10, and transforming 
growth factor (TGF)-β, as well as in diminished production 
of interferon (IFN)-γ and IL-17, both on systemic level and in 
the target tissue (CNS). Also, the data obtained in this study 
indicated that the increased proportion of Foxp3+ Tregs on 
systemic level and in CNS was associated with the amelioration 
of EAE. Moreover, the applied DCs managed to maintain such 
immunological profile throughout the disease, which indicates 
that ES L1-induced tolerogenic properties of DCs are function-
ally stable. Those results suggest that the immunomodulatory 
properties of ES L1-treated DCs are worth further research 
and the present study was designed to translate the knowledge 
obtained in animal model system on humans. However, con-
siderable differences in immune system exists between human 
and rodents (41), especially in DCs populations (42). Therefore, 
it is critical to investigate whether ES L1 antigens could induce 
similar tolerogenic properties of human DCs as well. Here, we 
found for the first time that T. spiralis ES L1 antigens indeed 
possess the ability to establish stable tolerogenic human DCs 
in vitro, which could be potentially useful to modulate autoim-
mune diseases in humans.
MaTerials anD MeThODs
The minimum information about tolerogenic antigen-presenting 
cells checklist was followed for the preparation of this manu-
script (43).
ethics statement
Animal experiments were performed according to institutional 
guidelines and were approved by the local Institutional Animal 
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Care and Use Committee of the Institute for the Application of 
Nuclear Energy.
Samples of human peripheral blood were obtained from 
healthy volunteers after written informed consent in accordance 
with the Declaration of Helsinki and approval by the Ethical 
Board of the Institute for the Application of Nuclear Energy.
antigen Preparation
Adult male Wistar rats, aged 10–12  weeks, were obtained from 
Military Medical Academy (Belgrade, Serbia) and were housed 
under standard conditions in animal room with access to food and 
water ad libitum. The rats were used for maintaining of T. spiralis  
strain (ISS 161). Muscle larvae were recovered by digestion of the 
carcasses in pre-warmed gastric juice (44), and kept under con-
trolled conditions (37°C, 5% CO2) in complete Dulbecco’s modified 
Eagle medium (DMEM) (Sigma), for 18 h (45). ES L1 antigens were 
obtained by dialysis and concentration of the culture supernatants 
to at least 4.2 mg/ml in sterile phosphate buffered saline (PBS). 
Potential endotoxin contamination in ES L1 antigens was neutral-
ized using SERVA Blue PrepProtein Endotoxin ExMicroKit (AMS 
Biotechnology, UK) according to the manufactures guidelines. 
Endotoxin levels in ES L1 pre paration, in the highest concentra-
tion used in the experiments (200 µg/ml), were lower than 0.5 EU/
ml [the limit provided by the US Food and Drug Administration 
guidelines (46)], as detected by the Limulus Amoebocyte Lysate 
turbidimetric test. The quality of ES L1 products was checked 
by Trichinella ELISA test (INEP, Serbia). Namely, ES L1 antigens 
were adhered to microtiter plates and their immunoreactivity 
was analyzed using reference sera with pre-defined titer of anti- 
T. spiralis specific antibodies, as described previously (47).
cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) from healthy 
blood donors were isolated by density gradient centrifugation on 
Lymphoprep gradient (Carl Roth). The monocytes were isolated 
by negative magnetic-activated cell sorting (MACS) from PBMCs, 
using the Monocyte Isolation kit (Myltenil Biotec), following their 
cultivation in CellGro DC medium (Cell Genix), supplemented 
with 100 ng/ml of human recombinant GM-CSF and 20 ng/ml of 
human recombinant IL-4 (both from R&D Systems) (complete 
DC growth medium). CD3+ T cells were isolated from PBMCs 
by negative MACS, using the Pan T cell isolation kit (Miltenyi 
Biotec), and they were used as responders in allogeneic coculture 
experiments with monocyte-derived DCs. The purity of CD14+ 
monocytes and CD3+ T cell populations was usually higher than 
90%, as evaluated by flow cytometry analysis (CyFlow Cube 6, 
Sysmex Partec GmbH, Görlitz, Germany) (data not shown).
To differentiate immature DCs, monocytes were cultivated in 
24-well plate, 0.5 × 106/well, in the complete DC growth medium 
for 5 days, refreshing the medium on Day 4. To assess the effect 
of ES L1 on DCs differentiation, the cells were cultivated dur-
ing this period in the presence of 10, 50, or 200 µg/ml of ES L1 
antigen, or without ES L1 (control DCs). The impact of ES L1 on 
the maturation of DCs was determined by adding ES L1 antigens 
to the culture of immature DCs on Day 4, for 48 h. To induce 
mature DCs, the cells were stimulated with LPS from Escherichia 
coli (500 ng/ml, Sigma-Aldrich) and human recombinant IFN-γ 
(50 ng/ml, R&D Systems) on Day 5, for the next 24 h. In some 
experiments, LPS (500 ng/ml) or polyinosininc:polycytidylic acid 
[Poly (I:C), 10 µg/ml] were used instead of LPS/IFN-γ, to inves-
tigate the stability of phenotypical and functional characteristics 
of DCs acquired after the pulsing with ES L1. To determine the 
role of toll-like receptors (TLR)2 and TLR4 on the DCs status 
induced by ES L1, immature DCs were treated with blocking 
antibodies against TLR2 and/or TLR4 (10 µg/ml each, both from 
BioLegend), or isotype control antibody (anti-rat IgG, eBiosci-
ence), 1  h before the treatment with ES L1. The phenotype of 
DCs was checked using flow cytometry, whereas DC culture 
supernatants were used for the cytokines analyses. DCs used for 
functional assays were extensively washed to prevent the transfer 
of free ES L1 or stimuli to the cocultures.
Flow cytometry
Dendritic cells cultivated with different agents were stained 
after the culture with the following antibodies/reagents: immu-
noglobulin (Ig)G1a negative control—peridinin–chlorophyll– 
protein complex (PerCP), IgG1 negative control—phycoerythrin 
(PE), IgG1 negative control—fluorescein isothiocyanate (FITC), 
IgG1a negative control—PE cyanine (Cy)5, IgG1 negative 
control—allophycocyanin (APC), anti-CD83-FITC, anti-CD86-
PE, anti CD40-APC, anti-CCR7-FITC, anti-TGF-β-PeCy5, 
anti-TLR4:PeCy5 (eBioscience), anti-CD1a-PE (Biolegend), 
anti-IL12p40/p70-PE, anti-indolamine 2,3 dioxygenase (IDO)-
1-APC, anti-Ig-like transcript (ILT)3-PE (R&D Systems), 
anti-IL-10-FITC (AbD Serotec), anti-CD14-FITC, and anti-
HLA-DR-PerCP (Miltenyi). The viability of DCs after the culture 
with ES L1 antigens was determined by 7-aminoactinomycin D 
(7AAD; Invitrogen) staining. For T cells staining, the following 
antibodies were used: anti-forkhead box (Fox)P3-PE, anti-CD4-
FITC, anti-CD4-PeCy5, anti-TGF-β-PE, anti-IL-4-PE, anti-
IL-10-PE (eBioscience), anti-CD25-PeCy5 (BD Pharmigen), 
anti-IL-10-FITC (AbD Serotec), IL-17A-PerCP (Biolegend), 
anti-IFNγ-FITC (R&D Systems), and appropriate negative iso-
type controls, as indicated.
For surface labeling, the cells were washed once in PBS 
containing 2% FCS and 0.1% Na-azide and then incubated with 
primary Abs for 30–60  min at 4°C. Intracellular staining was 
conducted after the surface staining, by using the flow cytometry 
fixation and permeabilization kit I (R&D). Intracellular staining 
of IFN-γ, IL-4, IL-10, IL-17, and TGF-β in T cells, was carried 
out after the 4-h activation of T cells with phorbol-12-myristate-
13-acetate (20 ng/ml, PMA) and ionomycin (500 ng/ml) in the 
presence of monensin (2 µM). For each analysis, more than 5,000 
cells were gated according to their specific side-scatter (SSC)/
forward-scatter (FSC) properties, thereby avoiding the cells with 
low SSC/FSC properties (predominantly dead cells), as indicated. 
Signal overlap between the FL channels was compensated before 
each experiment using single labeled cells, and non-specific fluo-
rescence was determined by using the appropriate isotype control 
antibodies and fluorescence minus one controls.
T cell Proliferation assay
In mixed leukocyte reaction assays, DCs treated with the dif-
ferent stimuli, as well as non-treated DCs, were cultured with 
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MACS-purified allogenic T cells in complete RPMI 1640 medium 
containing 10% FCS (Capricorn Scientific), l-glutamine, 2- 
mercaptoethanol (50  µM, Sigma), and antibiotics (penicillin, 
streptomycin, gentamicin, 1% each, ICN Galenika). T  cells 
(1 ×  105/well of 96-well plate) were cocultivated with different 
number of DCs (0.5 × 104, 0.25 × 104, 0.125 × 104) for 5 days in 
96-well round-bottom plates. The blank controls were T cells cul-
tivated separately. To measure the level of T cell proliferation, the 
cells were pulsed for the last 18 h of coculture with 3H-thymidine 
(1  μCi/well, Amersham). The radioactivity was measured by 
β-scintillation counting (LKB-1219 Rackbeta, Finland).
activation of T cells by allogenic Dcs
The capacity of ES L1-stimulated DCs to instruct the polariza-
tion of T cells was analyzed in allogenic stimulation assay. DCs 
(0.5 × 104/well, 96-well round-bottom plate) were cultivated with 
naive allogenic T lymphocytes in 1:20 ratio, for 6 days. To detect 
cytokines in the supernatants of allogenic stimulation assay, 
DC/T  cell cocultures were treated with PMA (20  ng/ml) and 
Ionomicin (500 ng/ml) for the last 4 h of coculture, followed by 
the harvesting of cell-free supernatants. The levels of cytokines 
produced in DCs cultures (IL-10, IL-12p70, TGF-β), as well 
as in DC/T  cell cocultures (IL-4, IL-10, IFN-γ, IL-17, TGF-β), 
were measured in cell-free supernatants by sandwich ELISA Kits 
(R&D). Additionally, T  cells were primed with DCs (2 ×  103/
well of 96-well round-bottom plate) at a 1:50 DC/T cell ratio for 
3 days and then expanded with IL-2 (2 ng/ml, R&D) for two more 
days (T primed cells, Tpr). In some experiments 1-methylthryp-
tophane (1-MT, 0.5 mM, Sigma), as an IDO-1 inhibitor (48), was 
added in the priming cocultures to assess the role of IDO-1 in the 
induction of Tregs. The Tregs were identified by flow cytometry 
based on their expression of CD4, CD25, FoxP3, IL-10, and 
TGF-β by flow cytometry.
suppressor assay
T cells primed with DCs (Tpr.) were extensively washed and then 
cocultivated with allogeneic PBMCs responder cells. PBMCs, 
1  ×  105 cells/well, were cocultured in 1:2 and 1:4 cell ratios 
with Tpr. (0.5 ×  105 and 0.25 ×  105 cells/well, respectively), in 
96-well round-bottom plates. In order to assess the proliferation 
of responder cells, PBMCs were pre-stained with 1  µM CFSE 
(Invitrogen) for 20 min, at 37°C, at density of 1 × 107 cells/ml. 
The proliferation of cells was stimulated with 8 µg/ml phytohe-
maglutinine (PHA), and after 5 days of coculture, the cells were 
harvested, stained with 20  µg/ml propidium iodide to exclude 
dead cells from the analysis, and the proliferation of responder 
T cells was measured by flow cytometry. The Proliferation Index 
(PI), i.e., the average number of cells derived from the initial cell, 
was calculated using proliferation fit statistics in FCS Express 4 
(De Novo Software, Glendale, CA, USA).
investigation of Pattern recognition 
receptors (Prrs) activation by es l1
HEK-Blue™ reporter cell lines expressing either TLR2, TLR3, 
TLR4, TLR5, TLR7, nucleotide-binding oligomerization domain-
like receptors (NOD)1, or NOD2 (InvivoGen, San Diego, CA, 
USA) (49) were used to evaluate the potential activation of these 
PRRs by ES L1. The stimulation of HEK-Blue™ cells by PRR 
agonists triggers the intracellular signaling events leading to 
the activation of nuclear factor (NF)-κB and activating protein 
(AP)-1 and the production of secreted alkaline phosphatase 
(SEAP). Therefore, the SEAP activities in supernatant correspond 
to the activation of the specific PRRs.
HEK-Blue™ hTLR2 (hkb-htlr2), HEK-Blue™ hTLR3 (hkb-
htlr3), HEK-Blue™ hTLR4 (hkb-htlr4), HEK-Blue™ hTLR5 (hkb-
htlr5), HEK-Blue™ hTLR7 (hkb-htlr7), HEK-Blue™ hNOD1 
(hkb-hnod1), and HEK-Blue™ hNOD2 (hkb-hnod2) cells were 
cultured in Dulbecco’s Modified Eagle’s culture medium (DMEM; 
Gibco, Thermo Fisher Scientific), supplemented with 100  U/ml 
penicillin, 100 µg/ml streptomycin, 0.3 mg/ml l-glutamine (Gibco; 
Pen–Strep–Glu 100×; Thermo Fisher Scientific, Rockford, IL, 
USA) and 10% (v/v) heat-inactivated HyClone FBS (30  min at 
56°C) (Thermo Fisher Scientific) at 37°C in 5% CO2/95% air. Cell 
lines (2.5 × 104/well, 96-well flat-bottom plates) were cultivated 
in 150  µl of culture medium. Cells were treated with 50  µl of 
various concentrations of ES L1 antigens (50, 5, and 0.05 µg/ml) 
or PRRs agonists: Pam3CSK4 (10  ng/ml) as TLR2 ligand, Poly 
(I:C) HMW (1 µg/ml) as TLR3 ligand, LPS (1 ng/ml) E. coli K12 
as TLR4 ligand, FLA-ST (50 ng/ml) as TLR5 ligand, Imiquimod 
(10 µg/ml) as TLR7 ligand, iE-DAP (25 µg/ml) as NOD1 ligand, 
and MDP (10 µg/ml) as NOD2 ligand (all from InvivoGen). After 
22–24 h incubation, supernatants were collected for determina-
tion of SEAP activity. QUANTI-Blue™ medium (180 µl) substrate 
and cell culture supernatant (20 µl) were added per well on a flat-
bottom 96-well ELISA plate. After 4 and 24 h of incubation at 37°C 
in 5% CO2, the levels of SEAP activity were analyzed by measuring 
the absorbance at 649 nm on a BioTek EL808 microplate reader 
and Gen5 Data Analysis Software (BioTek, VT, USA).
statistical analyses
Data are presented either from representative experiments or as 
mean ± SD of at least three experiments carried out with different 
DCs donors. Statistical analysis of the data was conducted using 
repeated measures ANOVA, followed by a Tukey’s posttest in 
PRISM5 (Graphpad software), and for p < 0.05, the differences 
were considered significant statistically.
resUlTs
es l1 antigens impair the Maturation  
of Dcs, without affecting Their 
Differentiation
Human monocytes cultured in complete DC growth medium 
in vitro differentiate into immature DCs, by upregulating CD1a 
and diminishing CD14 expression (50). To assess the influence 
of ES L1 antigens on differentiation of DCs, monocytes were 
differentiated with GM-CSF/IL-4 in the presence or absence of 
different doses of ES L1 antigens (10, 50, or 200 µg/ml), applied 
on Day 0. To exclude the possibility that the immunomodulatory 
effects of ES L1 antigens were due to their cytotoxicity, we first 
analyzed the percentage of dead (7AAD+) cells after 4  days of 
cultivation with ES L1. It was observed that the percentage of 
FigUre 1 | Effects ES L1 antigens on differentiation of dendritic cells (DCs). (a–e) Immature DCs were generated from monocytes in GM-CSF/interleukin-4 
supplemented medium in the presence of ES L1 (10, 50, and 200 µg/ml) antigens, or their absence (control), during 5 days. (a) Representative histograms  
from the analysis of 7AAD+ (dead) cells after the culture are shown and, (B) the summarized results from three different donors are shown as mean% ± SD.  
(c) Representative plots for CD1a and CD14 expression on DCs after 5 days of culture with ES L1 are shown, and (D) the summarized results from three different 
donors are presented as mean% ± SD. (e) DCs differentiated in the presence or absence of ES L1, were stimulated with LPS/IFN-γ on Day 5, and the expression  
of CD83, CD86, CD40, and HLA-DR was analyzed by flow cytometry after 24 h. The results collected with three different DC donors are shown as mean ± SD  
(see also Figure S1 in Supplementary Material, showing a representative experiment). *p < 0.05, **p < 0.01, ***p < 0.005 compared to corresponding control  
DCs, or as indicated (one-way ANOVA with Tukey’s posttest).
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7AAD+ DCs cultivated with 10 or 50 µg/ml was similar to the 
values obtained in control DCs cultures. In contrast, 200 µg/ml 
ES L1 increased the percentage of 7AAD+ cells up to 27% 
(Figures  1A,B). However, none of the applied ES L1 doses 
induced more than 30% of dead DCs which, according to ISO 
10933-5 (51), could be interpreted as the lack of cytotoxicity. The 
phenotypic analysis of DCs suggested that ES L1 did not interfere 
with DCs differentiation irrespective of the dosage applied, since 
the percentage of CD1a and CD14 on ES L1-treated DCs was 
similar to that on un-treated control DCs (Figures 1C,D).
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To evaluate whether the differentiation of DCs with differ-
ent ES L1 doses affect their subsequent maturation, DCs were 
stimulated with LPS/IFN-γ on Day 5 of culture, for the next 24 h. 
It was observed that differentiation with higher doses of ES L1 
(50 or 200  µg/ml) impaired severely the LPS/IFN-γ-induced 
upregulation of CD83, CD86, CD40, and HLA-DR, whereas the 
cultivation with 10 µg/ml ES L1 impaired only CD40 upregula-
tion (Figure 1E; Figure S1 in Supplementary Material). Although 
200 μg/ml of ES L1 had the strongest effect, it was not significantly 
different from the effect of 50 µg/ml ES L1.
human Dcs acquire stable semi-Mature 
Phenotype upon stimulation with es l1 
antigens
To assess whether ES L1 antigens exhibit similar effects on DCs 
maturation when added at latter periods of cultivation, the cells 
were pulsed with ES L1 antigens on Day 4 of cultures and then 
stimulated with LPS/IFN-γ on Day 5 for the next 24 h, or left 
un-stimulated. Considering the negligible effects of 10 µg/ml of 
ES L1 on LPS/IFN-γ-induced DCs maturation and significant 
immunomodulatory effect of 50  µg/ml of ES L1 without an 
increased cytotoxicity, further experiments were carried out with 
50 µg/ml of ES L1 to monitor the functional significance of ES L1 
on DCs maturation. The analysis of maturation markers on DCs, 
48 h after the treatment with ES L1, showed that the expression 
of HLA-DR, CCR7, CD83, and CD86 were somewhat upregu-
lated, but not significantly, compared to the control immature 
DCs (Figure 2A; Figure S2 in Supplementary Material). ES L1 
treatment significantly upregulated only the expression of CD40 
(Figure 2A; Figure S2 in Supplementary Material), all of which 
suggested that ES L1 induce a semi-mature phenotype of DCs. 
Similar results were obtained when the treatment with ES L1 
lasted only 24 h (data not shown). In contrast to ES L1-treated 
DCs, the expression of all surface markers after the 24h-stimula-
tion with LPS/IFN-γ was significantly upregulated, as expected 
for type 1 inflammatory DCs induced by this cocktail (52). 
However, DCs treated with 50 µg/ml of ES L1 before LPS/IFN-γ 
stimulation displayed an impaired upregulation of maturation 
markers (Figure  2A), confirming that the effect of ES L1 was 
limited to the maturation stage of DCs.
To investigate the effect of ES L1 antigens on DCs’ cytokines 
production, the percentages of IL-10, IL-12, and TGF-β positive 
DCs were determined by intracellular staining (Figures 2B,C), 
and the cytokine levels were analyzed in DCs culture supernatants 
(Figure 2D). Both analyses showed that the levels of IL-12 in ES 
L1-treated DCs were unchanged compared to control immature 
DCs, i.e., ES L1 failed to induce the production of IL-12 by DCs. 
On the other hand, ES L1 significantly increased the percentage 
of IL-10+ DCs and the levels of IL-10 in DCs culture supernatants 
(Figures 2C,D). The percentage of TGF-β+ DCs also increased 
significantly after the ES L1 treatment, compared to control DCs, 
but this was not followed by increased levels of TGF-β in the 
culture supernatants (Figures 2B–D).
To investigate the functional stability of ES L1-treated DCs, 
the cells were challenged with different maturation stimuli 
24 h after the treatment with ES L1 antigens. The stimulation 
of DCs with LPS/IFN-γ for 24 h, expectedly, induced a strong 
upregulation of surface maturation markers (Figure 2A; Figure 
S2 in Supplementary Material), IL-12 expression, and its pro-
duction by DCs. However no such upregulation occurred if DCs 
were treated with ES L1 before the challenge with LPS/IFN-γ 
(Figures  2B–D). The expression of TGF-β in ES L1-treated 
DCs, after the challenge with LPS/IFN-γ, remained significantly 
higher compared to control LPS/IFN-γ-matured DCs. Curiously 
enough, the levels of TGF-β in DCs culture supernatants did 
not correspond to the percentages of DCs expressing TGF-β 
intracellularly, which could be a consequence of the autocrine 
uptake of the produced TGF-β (53). On the other hand, the 
expression of IL-10 by ES L1-treated DCs matured with LPS/
IFN-γ and its production levels were not significantly different 
from the values obtained with control LPS/IFN-γ-matured DCs 
(Figures 2B–D).
Considering the inhibitory effects of IFN-γ on IL-10 produc-
tion by DCs (54), we wondered whether the use of LPS alone, 
as a maturation stimulus, would exhibit different effects on the 
phenotype and cytokines production by ES L1-treated DCs. 
ES L1-treated DCs exhibited similar resistance to LPS-induced 
phenotypic maturation and IL-12 expression, as when LPS/
IFN-γ was used as a stimulus, while the expression of IL-10 in 
ES L1-treated LPS-matured DCs was significantly higher com-
pared to control LPS-matured DCs (Figure S3 in Supplementary 
Material). The mitigated effect of LPS/IFN-γ or LPS alone on the 
phenotype and cytokine production by ES L1-treated DCs was 
not a consequence of ES L1-induced downregulation of TLR4 on 
DCs, since its expression was not changed significantly 48 h after 
the ES L1 treatment (Figure S4 in Supplementary Material).
Since LPS and LPS/IFN-γ stimulation includes a TLR4-
dependent induction of DCs maturation (55), we also tested 
whether ES L1-treated DCs display similar maturation resistance 
to other TLR stimuli, such as the stimulation via TLR3 with 
its agonist, Poly (I:C). The data showed that ES L1 impaired 
significantly the upregulation of HLA-DR, CD40, and IL-12 by 
DCs, but not CD83 and CD86, upon the Poly (I:C) stimulation. 
Additionally, ES L1-treated Poly (I:C)-matured DCs produced 
significantly higher levels of IL-10 compared to control Poly 
(I:C)-matured DCs (Figure S5 in Supplementary Material). These 
data suggested that the treatment of DCs with ES L1 impeded full 
maturation of DCs by different maturation stimuli, showing the 
stability of ES L1-treated DCs.
Dcs Treated with es l1 acquire limited 
allo-stimulatory capacity and Provoke 
Th2 and regulatory responses
To assess the capacity of human DCs to influence the prolifera-
tion of T cells after the treatment with ES L1, coculture of DCs 
and allogeneic MACS-purified CD3+ T cells was performed, and 
the T cell proliferation was determined based on 3H-thymidine 
incorporation level. ES L1-treated DCs had a weaker capacity to 
stimulate T  cell proliferation compared to both immature and 
LPS/IFN-γ-matured DCs (Figure  3A). The limited T  cell pro-
liferation capacity was preserved even when ES L1-treated DCs 
were challenged with LPS/IFN-γ.
FigUre 2 | The maturation capacity of dendritic cells (DCs) treated with ES L1 antigens. (a–D) Immature DCs were treated with ES L1 antigens (50 µg/ml) on Day 4 
of culture for 24 h and then additionally activated or not with LPS/interferon (IFN)-γ for the next 24 h, followed by flow cytometry analysis. (a) The percentages of 
CD83, CD86, HLA-DR, CCR7, and CD40 expression by DCs are shown as mean ± SD from four different experiments (see also Figure S2 in Supplementary 
Material for a representative experiment). (B) Representative analysis of interleukin (IL)-10, IL12p40/p70, and transforming growth factor (TGF)-β expression within 
DCs are shown, and (c) the summarized results are presented as fold change of cytokines expression as mean ± SD from seven different experiments. (D) The 
levels of IL-10, IL-12p70, and TGF-β (picograms/milliliter) in DCs culture supernatants were measured by ELISA test. *p < 0.05, **p < 0.01, ***p < 0.005 compared 
to control, or as indicated (one-way ANOVA with Tukey’s posttest).
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FigUre 3 | Allo-stimulatory and T helper polarizing capacity of ES L1-pulsed dendritic cells (DCs). (a–D) DCs treated with ES L1 antigens (50 µg/ml) and/or LPS/
interferon (IFN)-γ were washed thoroughly and then cocultured with magnetic-activated cell sorting-purified allogenic T cells (Tly) (1 × 105/well) for 6 days in two 
DC:T cell ratios (1:10 and 1:20). (a) The proliferation in cocultures was measured by 3H-thymidin incorporation assay, and Tly cultivated alone were used as a blank 
control. (B) The concentration of indicated cytokines were determined in the supernatants of PMA/ionophore-treated DC:T cell cocultures at 1:20 cell-to-cell ratio, 
respectively, by specific ELISA tests. (c) The percentage of cytokines expression measured intracellularly by flow cytometry, within the T cells cocultivated with DCs 
as in (B) and treated with PMA/Ionophore/monensin for the last 4 h, are shown as mean% ± SD of four experiments with different DCs donors. *p < 0.05, 
**p < 0.01, ***p < 0.001 compared to control, or as indicated by line (one-way ANOVA with Tukey’s posttest). (D) The analysis of the intracellular cytokines in T cells 
was carried out after the surface staining of CD4, as indicated on representative dot plots collected from two experiments.
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The Th polarization capacity of ES L1-treated DCs was 
assessed by measuring the levels of IFN-γ, IL-17, IL-4, IL-10, and 
TGF-β in DCs/T  cell cocultures (Figure  3B) and by analyzing 
the expression of these cytokines within gated CD4+ and CD4− 
(more than 98% CD8+) T cell population (Figures 3C,D) after 
the stimulation with PMA/ionophore. The results suggested that 
ES L1 potentiated DC-mediated induction of Th2 and regula-
tory type of immune response, as judged by the increased IL-4, 
IL-10, and TGF-β expression by T cells and their production in 
DC/T  cell cocultures. The increased capacity of ES L1-treated 
DCs for the induction of regulatory cytokines in T  cells was 
detected in both CD4+ and CD8+ T cell population (Figure 3D). 
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After the challenge with LPS/IFN-γ, the capacity of ES L1-treated 
DCs to induce TGF-β-producing T  cells increased even more. 
Their capacity to induce Th2 cells remained significantly 
higher than the capacity of control LPS/IFN-γ-matured DCs, 
whereas the capacity to induce IL-10-producing T cells was similar 
to the capacity of control mature DCs. Additionally, ES L1-treated 
DCs displayed an impaired potential to induce Th17  cells in 
the absence of stimuli, and an impaired Th1/Th17 polarization 
capacity after their challenge with a strong Th1/Th17 polarizing 
cocktail, LPS/IFN-γ, which was confirmed by the analyses of both 
soluble products and intracellular cytokines expression in T cells 
(Figures  3B–D). Taken together, ES L1-treated DCs displayed 
a clear shift in polarizing capacity, away from Th1/Th17, toward 
increased regulatory and Th2 type of immune response.
Dcs Pulsed with es l1 antigens have 
Tolerogenic Properties
Since DCs upon the treatment with ES L1 antigens acquire 
semi-mature phenotype, limited allo-stimulatory capacity, and 
shift the immune response toward Th2 and regulatory type, we 
presumed that ES L1-treated DCs possess tolerogenic properties. 
In addition to reduced pro-inflammatory phenotype and func-
tions, the tolerogenic DCs express tolerogenic markers, such as 
IDO-1 and ILT-3, and display an increased capacity to induce 
Tregs (56, 57). Therefore, we first analyzed the expression of 
IDO-1 and ILT-3 by DCs under the influence of ES L1 antigens, 
in the presence or absence of additional stimulation with LPS/
IFN-γ (Figures  4A,B). The results showed that ES L1 induce 
the expression of both markers on DCs, but not significantly. 
However, the expression of IDO-1 was significantly increased 
after the challenge of ES L1-treated DCs with LPS/IFN-γ. The 
expression pattern of ILT-3 showed similar trend, but the differ-
ences were not significant statistically.
The percentage of Tregs in coculture with DCs was deter-
mined based on their high expression of CD25 and FoxP3 
within CD4+ T  cells, to distinguish them from transiently 
activated CD25+Foxp3+ Th cells. ES L1-treated DCs induced 
a significant increase in the percentage of CD4+CD25hiFoxp3hi 
compared to control cells (twofold), and retained that ability 
even after LPS/IFN-γ challenge (Figures 4C,D). The observed 
expansion of Tregs was IDO-1 dependent, as it was demon-
strated that the addition of 1-MT in the cocultures decreased 
significantly the percentages of CD4+CD25hiFoxp3hi cells 
(Figures  4C,D). All CD4+CD25hi T  cells were positive for 
TGF-β, but it was found that ES L1-treated DCs significantly 
increased the expression of TGF-β within CD4+CD25hi T cells, 
compared to the control DCs, and this ability of ES L1-treated 
DCs was even more pronounced after their challenge with 
LPS/IFN-γ (Figures 4E,F). Moreover, the expression of IL-10 
within CD4+CD25hi T cell population was fourfold higher upon 
priming with ES L1-treated DCs than after the priming with 
control DCs. However, such an upregulation of IL-10 within 
CD4+CD25hi T cells was not observed when DCs were stimu-
lated additionally with LPS/IFN-γ (Figures 4E,F).
Taken together, the above results suggested that ES L1 indeed 
potentiated the tolerogenic phenotype and functions of DCs, 
which induced Tregs in IDO-1-dependent manner, especially 
after the challenge with LPS/IFN-γ.
T cells Primed by es l1-Treated Dcs 
exhibit suppressive activity
To investigate whether an increased percentage of 
CD4+CD25hiFoxp3hi Treg have any functional significance, the 
T cell population primed with DCs (Tpr) was cocultivated with 
CFSE-labeled PBMCs (responders) in the presence of PHA. 
A flow cytometry analysis of the responder cells’ proliferation 
clearly suggested that T cells primed with ES L1-treated DCs exhib-
ited a stronger capacity to inhibit the proliferation of responder 
cells in both 1:2 and 1:4 Tpr:responder cell ratios (Figures 5A,B). 
Similar results were obtained with T  cells primed with LPS/
IFN-γ-stimulated ES L1-treated DCs, as demonstrated by their 
increased potential to suppress the responder cells proliferation 
in 1:2 cell-to-cell ratio. The results suggested that ES L1-treated 
DCs retained the ability to induce suppressive T cell populations 
even in inflammatory environment. Since the percentage of Tregs 
increased significantly after the priming with ES L1-treated DCs, 
the observed suppressive activity of the primed T cell population 
may be ascribed to the effects of Tregs as well.
es l1 antigen activates Tlr2 and Tlr4
The data about the receptors that recognize T. spiralis antigens 
are scarce. Having in mind that PRRs are a key element of the 
innate immune system and have important role in detection of 
pathogens and subsequent activation of DCs, the interaction 
between different PRRs (TLRs and NODs) with ES L1 antigens 
was investigated. The study was performed on HEK-Blue™ 
reporter cell lines expressing the individual TLRs (TLR2, -3, 
-4, -5, -7), NOD1, or NOD2 receptors. The activation of PRRs 
was indicated by SEAP activation in culture supernatants of 
stimulated cells. All used HEK-Blue™ cell lines were treated 
with ES L1 antigens, while the cells pulsed with corresponding 
TLR or NOD agonists were used as positive controls, and the 
cells cultivated only in medium were used as negative control 
(Figure 6).
Stimulation of HEK-hTLR2 cells with ES L1 induced an 
increased level of SEAP activity after 4 and 24 h (Figures 6A,B 
respectively) compared to negative control, indicating that ES 
L1 activates TLR2-mediated signaling events. ES L1 treatment 
of HEK-hTLR4 cells resulted in a significantly increased level of 
alkaline phosphatase activity after 4 h (Figure 6C) compared to 
control, and after 24 h (Figure 6D), the level of enzyme activity 
was similar to the one observed with TLR4 agonist (LPS, 1 ng/ml), 
suggesting that ES L1 also activated TLR4. HEK-hTLR3, HEK-
hTLR5, HEK-hTLR7, HEK-hNOD1, and HEK-hNOD2 cell lines 
cultivated in the presence of ES L1 antigens, after 4 h (data not 
shown) and after 24 h, showed no statistically significant change 
in SEAP activity, compared to control cells, unlike the cells treated 
with specific PRR ligands as described (Figures  6E–I). The 
obtained results suggested strongly that ES L1 antigens engage 
TLR2 and TLR4 and activate NF-κB and AP-1-mediated signal-
ing events by these receptors, while TLR3, TLR5, TLR7, NOD1, 
and NOD2 receptors do not participate in ES L1-mediated effects.
FigUre 4 | Continued
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FigUre 5 | The suppressive potential of T cells primed with ES L1-pulsed dendritic cells (DCs). (a,B) magnetic-activated cell sorting-purified CD3+ T cells  
(0.5 × 104 or 0.25 × 104 cells/well) primed with DCs (Tpr.), as described, were harvested after 6 days, washed, and then cocultivated with third-part allogeneic 
CFSE-labeled Peripheral blood mononuclear cells (PBMCs) (Resp.) (1 × 104 cells) in 1:2 and 1:4 cell-to-cell ratio, respectively, in the presence of phytohemaglutinine 
(PHA) (8 µg/ml) for the next 5 days. (a) Representative histograms from one experiment, with Tpr:Resp. 1:2 cell ratio, is shown, and (B) the summarized results from 
four different experiments are shown as mean PI (the average number of cells derived from the initial cell) of Resp. ± SD. *p < 0.05, compared as indicated by line 
(one-way ANOVA with Tukey’s posttest).
FigUre 4 | Tolerogenic properties and functions of ES L1-treated dendritic cells (DCs). (a) DCs treated with ES L1 antigens (50 µg/ml) and/or LPS/interferon 
(IFN)-γ, as described, were analyzed for IDO-1 and immunoglobulin-like transcript (ILT)-3 expression, as indicated on representative histograms. (B) The summarized 
results on IDO-1 and ILT-3 expression on three different DC donors is shown as mean% ± SD. (c) DCs treated as in (a) were washed thoroughly and then 
cocultivated with magnetic-activated cell sorting-purified allogenic T cells (1 × 105/well) (DC:T cell ratio 1:50), for 3 days and then re-stimulated with interleukin  
(IL)-2 (2 ng/ml) for another 3 days, all in the presence or absence of 1-MT (0.5 mM). Representative analysis of CD25hiFoxP3hi cells within CD4+ T cells from  
one experiment is shown, and (D) the summarized results are shown as the mean fold change in regulatory T cells % ± SD from four different experiments.  
(e) Representative analysis of transforming growth factor (TGF)-β and IL-10 within CD4+CD25hi T cell population is shown, and (F) the summarized results collected 
from four different experiments are shown as mean fold change in mean fluorescence intensity (MFI) (TGF-β) or % (IL-10) within CD4+CD25hi T cell population ± SD. 
*p < 0.05, **p < 0.01, ***p < 0.005 compared as indicated by line (one-way ANOVA with Tukey’s posttest).
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Tlr2 and Tlr4 are involved in es l1-
Mediated induction of semi-Mature Dcs
Considering that ES L1 antigens activate TLR2 and TLR4, the 
next step was to investigate the relevance of this interaction for 
the development of semi-mature DCs by ES L1 antigens. For this 
purpose, TLR2 and TLR4 receptors were blocked individually or 
simultaneously using specific monoclonal blocking antibodies, 
prior to DCs treatment with ES L1 antigens. In the presence of 
the specific blocking antibodies, the expression of DCs surface 
markers upon ES L1 treatment was significantly changed com-
pared to control DCs treated with ES L1 antigens in the presence 
of isotype control antibody. Namely, the expression of CD83 was 
significantly lower, while CD86, HLA-DR, and CD40 expression 
were significantly higher compared to control ES L1-treated DCs 
(Figures 7A,B).
Additionally, the differences in cytokines production by DCs 
were analyzed in the presence of specific blocking or isotype 
control antibodies upon the ES L1 treatment (Figure 7C). In case 
when TLRs were specifically blocked either individually or simul-
taneously, the anti-inflammatory properties of ES L1-treated 
DCs were diminished, i.e., the concentration levels of IL-12p70 
were significantly higher and the levels of IL-10 and TGF-β 
were significantly lower compared to those observed in DCs 
treated with ES L1 and isotype control antibody. The treatment 
of DCs with isotype control antibody, as well as the blocking of 
receptors without subsequent treatment with ES L1 antigens, 
resulted in the same DCs maturation profile as observed with 
non-stimulated DCs (data not shown). The results obtained 
by individual blocking of TLR2 and TLR4 indicated that 
both receptors are involved in ES L1-driven DC phenotype. 
Simultaneous blocking of two receptors gave no phenotypic or 
functional changes compared to individual blocking, suggesting 
the absence of synergistic effect.
DiscUssiOn
A number of studies have dealt with in vitro generation of DCs 
from monocytes that can be manipulated to acquire tolerogenic 
properties (35, 56, 58–60). These cells were shown to have 
an immature or semi-mature phenotype, low production of 
inflammatory and increased production of anti-inflammatory 
cytokines, the ability to present antigens in a tolerogenic form, 
and consequently, an increased capacity to induce Tregs. 
Tolerogenic DCs are considered as a promising tool for develop-
ment of cell-based therapy applicable in the treatment of auto-
immune diseases, chronic inflammation, and transplantation 
FigUre 6 | Continued
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FigUre 7 | Role of TLR2 and TLR4 in ES L1 antigen-induced dendritic cells (DCs) maturation and cytokine production. (a–c) Immature DCs were incubated with 
ES L1 in the presence of isotype control, or specific TLR2 and/or TLR4 blocking antibodies (10 µg/ml). After 48 h, the expression of surface markers (CD83, CD86, 
HLA-DR, and CD40) was measured by flow cytometry and the cytokine levels were determined in culture supernatants by ELISA test or by intracellular staining.  
(a) Representative analysis of surface markers expression is shown, and (B) the summarized results are shown as fold change in percentage (%) of markers 
expression ± SD from three different experiments. (c) Cytokine levels (picograms/milliliter) for interleukin (IL)-10 and IL-12p70 measured in DCs culture supernatants 
by ELISA test, and transforming growth factor (TGF)-β expression (% fold change) determined by flow cytometry, are shown as mean ± SD of three different 
experiments. *p < 0.05, **p < 0.01, ***p < 0.005 as indicated by line (one-way ANOVA with Tukey’s posttest).
FigUre 6 | Interaction of ES L1 antigen with pattern recognition receptors (PRRs) on HEK-Blue™ cell lines. HEK-Blue™ cell lines transfected with a single specific 
human PRR (TLR2, 3, 4, 5, 7, NOD1, and 2) were treated with ES L1 or PRR agonists for 24 h, followed by the analyses of secreted alkaline phosphatase (SEAP) 
levels (OD 649 nm) released in culture medium at two time points (4 and 24 h after the substrate addition). Pam3CSK4 (10 ng/ml), ES L1 (5 µg/ml)—incubation 
period 4 (a) and 24 h (B); LPS (1 ng/ml) Escherichia coli K12, ES L1 (5 µg/ml)—incubation period 4 (c) and 24 h (D); Poly (I:C) HMV (1 µg/ml), ES L1 (5 µg/ml)— 
incubation period 24 h (e); FLA-ST (50 ng/ml), ES L1 (5 µg/ml)—incubation period 24 h (F); imiquimod (10 µg/ml), ES L1 (5 µg/ml)—incubation period 24 h  
(g); iE-DAP (25 µg/ml) ES L1 (50 µg/ml)—incubation period 24 h (h); MDP (10 µg/ml), ES L1 (50 µg/ml)—incubation period 24 h (i). Results are shown as 
mean ± SD from three different experiments *p < 0.05, **p < 0.01, ***p < 0.001 compared with control (medium) (one-way ANOVA with Tukey’s posttest).
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therapy (61). Our previous results obtained on animal model 
system demonstrated the capacity of T. spiralis products to induce 
the development of DCs with tolerogenic properties (40), which 
successfully ameliorated autoimmune disease in animal models 
(16). However, further development of cell therapies based on 
ES L1 antigens require comprehensive studies on human DCs 
model system, which have not been conducted so far. Here, we 
showed for the first time that T. spiralis ES L1 antigens represent 
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a promising new tool for the generation of human tolerogenic 
DCs in  vitro. In contrast to other protocols for generation of 
DCs, such as those which include vitamin D3 (26, 27) or IL-10 
(31), DCs cultivated with ES L1 antigens from Day 0, even 
with high doses, displayed an unaltered differentiation pattern, 
i.e., complete downregulation of CD14 and upregulation of 
CD1a in the presence of GM-CSF and IL-4. These results sug-
gested that the effects of ES L1 antigens are restricted to differ-
entiated DCs population, but not on their monocyte precursors. 
Although the physiological significance of this finding is still 
unclear and require independent investigation, such property 
of ES L1 could have evolved as a result of tight regulation of the 
host immune response by the parasite. This kind of modula-
tion is aimed specifically to prevent the host immune response 
against the parasite itself, but it also mitigates the unwanted 
immune responses like those to autoantigens and allergens, 
consequently increasing the chances of host survival (37). Upon 
contact with ES L1 antigens, human monocyte-derived DCs 
acquired semi-mature phenotype, characterized by: low expres-
sion of HLA-DR, co-stimulatory molecules and CCR7; moder-
ate expression of CD40; a clear anti-inflammatory cytokine 
profile, i.e., low production of IL-12 along with the enhanced 
production anti-inflammatory/regulatory cytokines, IL-10 and 
TGF-β, even after the challenge with pro-inflammatory stimuli. 
In line with this, an increased ratio of IL-10/IL-12 in DCs was 
found to contribute significantly to their tolerogenic functions 
and increased capacity to expand Tregs and downregulate dif-
ferentiation of Th1 and Th17  cells (50, 61). CCR7 expression 
by IL-10-producing DCs was shown critical for their migra-
tion to lymphoid organs and polarization of naïve T cells into 
Tregs (62–64). Somewhat increased expression of CCR7 by ES 
L1-treated DCs and their tolerogenic potential are in line with 
these findings. High production of IL-10 and TGF-β could be 
responsible for the decreased expression of co-stimulatory mol-
ecules and blocking of IL-12 production by DCs, as suggested by 
other findings (59). Also, synergistic effects of IL-10 and TGF-β 
were shown to result in enhanced tolerogenic properties of DCs 
and their higher potential to induce IL-10-producing Tregs 
(65), which is in line with the properties of ES L1-treated DCs 
observed in this study.
The stability of tolerogenic DCs and preservation of anti-
inflammatory phenotype in inflammatory surrounding is the 
most important issue when creating cell-based therapies for auto-
immune diseases (61). TLRs were shown to be critically involved 
in the recognition of damage-associated molecular patterns 
(DAMPs), driving the unwanted inflammatory response in auto-
immune diseases (66). In addition to TLR3, which was shown to 
be involved in the recognition of self-RNAs released from necrotic 
synovial fluid cells in rheumatoid arthritis patients (67), TLR4 has 
been implicated in the recognition of various DAMPs in different 
autoimmune processes (68). In line with this, ES L1-treated DCs 
displayed the resistance to the maturation induced by both TLR3 
(Poly I:C) and TLR4 (LPS) agonist in particular. In contrast to 
Poly (I:C) and LPS, known to induce predominantly Th1 (56) and 
a mixed Th1/Th2 response (69), respectively, LPS/IFN-γ cocktail 
is known to induce inflammatory type 1 DCs (52), which are able 
to induce both Th1- and Th17-mediated immune response (50). 
Both, Th1 and Th17  cells were shown to be critically involved 
in the pathogenesis of chronic inflammation and autoimmun-
ity (70). DCs maturated in the presence of ES L1 retained their 
tolerogenic properties regardless of activation with LPS/IFN-γ 
since, no noticeable change in the expression of surface mark-
ers and cytokine profile was observed. ES L1 antigens affected 
the maturation and cytokines production of DCs in a way that 
resembles tolerogenic DCs obtained under the influence of some 
immunosuppressive drugs (27, 28, 60) or immunosuppressive 
cytokines (65), but presumably via different mechanisms.
ES L1-treated DCs, even after the challenge with LPS/IFN-γ, 
exhibited a reduced capacity to induce T  cell proliferation in 
mixed leukocyte reactions, which is in accordance with their 
observed semi-mature phenotype and tolerogenic functions. 
The experiments were performed using cells from healthy 
individuals. Due to HLA-restriction, the allogeneic coculture 
system applied in our study includes the response of a limited 
naïve T  cell population that are able to respond to allogeneic 
MHC complexed with self-peptides (71). This model system 
may better reflect the potential response to ES L1-treated 
DCs in  vivo, compared to models with a polyclonal stimula-
tion of T  cells, especially since recent findings suggested that 
T. spiralis-secreted components are structurally related to some 
human cell components (39), so only a limited repertoire of 
naïve T  cells may be able to respond. Moreover, these DCs 
impaired inflammatory Th1 and Th17 cell responses manifested 
as both reduced production of IFN-γ and IL-17 cytokines and 
the percentage of Th1 and Th17 cells, respectively. Lower Th1 
polarizing capacity of ES L1-treated LPS/IFN-γ-matured DCs 
might be a consequence of their low capacity to produce IL-12, 
a known Th1-polarizing factor (72). The fact that ES L1-treated 
DCs enhanced TGF-β production by T cells may also explain 
diminished production of Th1 polarization capacity and 
reduced allogenic proliferation, since TGF-β was shown to be 
critically involved in both processes (73). Although it is known 
that TGF-β contributes to regulatory as well as to Th17 type of 
immune response, there is evidence that low levels of TGF-β 
promote Th17 response, while increased TGF-β influences the 
elevated Foxp3 expression, hence promoting the expansion of 
Tregs (74). Since IFN-γ and IL-17 contribute in the genesis of 
autoimmune diseases (75, 76), the capacity of ES L1-induced 
tolerogenic DCs to reduce the production of these cytokines 
could favor the potential applicability of these DCs in the treat-
ment of autoimmune diseases. The observations, that secretory 
products from different parasitic worms heavily skew the 
immune response toward Th2 type via DCs while inhibiting 
Th1 and Th17 responses (34), are in line with the finding that 
ES L1-primed DCs induced Th2 type response, as indicated by 
significantly expanded Th2 cells and elevated IL-4 production. 
In addition to lowering Th1 response, an increased Th2 polari-
zation could also be related to moderately increased expression 
of CD40 on DCs upon stimulation with ES L1, as it was shown 
that CD40 is critically involved in the induction of Th2 cells by 
DCs, especially during helminths infection (77).
Besides the suppression of inflammatory immune response 
and the enhancement of Th2 type of response, ES L1-treated 
DCs demonstrated the ability to induce the expansion of 
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CD4+CD25hiFoxp3hi T  regulatory cells. This expansion was 
reduced upon addition of 1-MT, an IDO-1 inhibitor (48) dur-
ing the coculture, suggesting that Tregs inducing capacity of ES 
L1-treated DCs is IDO-1 dependent. IDO-1-mediated actions 
on the induction of Tregs include both deprivation of trypto-
phan and kynurenine-dependent induction of Tregs via aryl 
hydrocarbon receptor (78). An increased expression of IDO-1 
in DCs additionally treated with LPS/IFN-γ could be explained 
by the fact that IFN-γ is a strong inducer of IDO-1 (79). The 
results from these experiments also suggested that IDO-1 is 
more involved in the induction of Tregs by ES L1-treated DCs 
matured with LPS/IFN-γ than DCs treated with ES L1 only, as 
a stronger inhibition of Treg induction was obtained with the 
former. Therefore, DCs treated with ES L1 could have utilized 
additional mechanisms besides IDO-1, such as IL-10- or ILT-
3-mediated induction of Tregs, both of which were shown to 
be involved in the induction of Tregs by tolerogenic DCs (61). 
Tregs are involved in the suppression of effector T-cell activity 
and maintenance of immunologic self-tolerance, as underlying 
processes in the modulation of autoimmune diseases (80). The 
finding that Treg-inducing capacity of ES L1-treated DCs is 
retained, even after the challenge with strong pro-inflammatory 
stimuli, is in agreement with previous findings on tolerogenic 
DCs primed by immunomodulatory molecules or immunosup-
pressive drugs (27, 81). Tregs induced by ES L1-treated DCs 
upregulated the production of IL-10 which may be the conse-
quence of high IL-10/IL-12 ratio observed in ES L1-treated DCs 
that induced the expansion of Tregs, as previous findings on 
the mechanisms of Tregs induction suggest (61, 82). The same 
population of Tregs showed an elevated expression of TGF-β, 
probably due to the increased production of IL-10 and TGF-β by 
DCs (61). Although both TGF-β and IL-10 exhibit immunosup-
pressive functions, they were also shown to negatively regulate 
each other (83, 84). These findings could partially explain why 
Tregs induced by ES L1-treated DCs expressed predominantly 
IL-10, whereas Tregs induced by LPS/IFN-γ-matured ES 
L1-treated DC produced predominantly TGF-β. It is also pos-
sible that different mechanisms of tolerogenic induction were 
triggered after the maturation of ES L1-treated DCs, but these 
hypotheses require further investigations. A relevant criterion 
for the evaluation of optimal DCs properties for tolerance induc-
tion is their capacity to induce Treg cells that are able to inhibit 
allogeneic T cell proliferation, and this property was observed 
in some tolerogenic DCs like those primed by IL-10 (31, 57). 
We showed here that T  cells primed with ES L1-treated DCs 
successfully suppressed the proliferation of allogeneic PBMCs, 
probably due to increased prevalence of Tregs cells in resulting 
T cell population, as well as other suppressive T cell population 
induced by ES L1-treated DCs.
Using HEK-Blue™ reporter cells lines expressing individual 
TLR or NOD-like receptors, we identified for the first time 
TLR2 and TLR4 as receptors that interact and induce intacel-
lular signaling after ligation of ES L1 antigens. These results are 
consistent with the studies that have shown the interaction of 
TLR2 or TLR4 with other helminth antigens. For example, lipid 
fractions and lysophosphatidylserine of helminth Schistosoma 
mansoni and lipid of Ascaris lumbricoides reacted with TLR2 
on DCs and mediate their differentiation into cells that induce 
Th2 and regulatory immune responses (85, 86). Lacto-N-
fucopentaose III of S. mansoni and ES 62 glycoprotein secreted 
by Acanthocheilonema vitae, were shown to activate TLR4 
receptor and lead to consequent polarization of T cell responses 
toward Th2 (87, 88). Even though the microbial and helminthic 
products can engage the same TLRs, they can, most probably 
in combination with other PRRs, initiate different downstream 
signaling pathways that could lead to different immune response 
polarization. The precise underlying mechanisms are yet to be 
investigated.
The critical relevance of both TLR2 and TLR4 interaction 
with ES L1 antigens for the induction of tolerogenic properties 
in human DCs was demonstrated by blocking these two recep-
tors before adding ES L1 antigens. Tolerogenic properties of ES 
L1-stimulated DCs were compromised when TLR2 and TLR4 
were blocked, indicating, for the first time, that T. spiralis ES L1 
antigens mediate phenotypical and functional maturation of DCs 
mainly via TLR2 and TLR4. The importance of both TLR2 and 
TLR4 was also demonstrated for the interaction with S. mansoni 
antigens (85, 89). Signaling via most TLRs normally results in 
the production of pro-inflammatory cytokines by DCs (90). 
However, helminth (and some microbial) products trigger Th2 
and regulatory responses via interaction with TLRs (91). It is 
frequently suggested that stimulation of TLR2 is associated with 
Th2 immune response, while activation of DCs delivered through 
TLR4 results in Th1 type of response. ES L1 antigens interacted 
with both receptors on DCs, which resulted in the induction of 
anti-inflammatory responses. Moreover, ES L1 rendered DCs 
poorly responsive to TLR4-mediated induction of matura-
tion, not via suppression of TLR4 expression, since we showed 
that ES L1 did not alter the expression of TLR4, but rather via 
modulation of downstream signaling events, and/or engagement 
of some other receptors expressed on DCs. Since ES L1 antigens 
are complex mixture of molecules, it is reasonable to assume that 
other PRRs are also involved in ES L1 recognition and binding. 
Indeed, it was revealed that ES L1 components are ligands for 
C-type lectin receptors, mannose receptor (92), and DC-SIGN 
(manuscript in preparation). Binding to lectin receptors could 
modulate intracellular signaling triggered by TLRs and affect 
DCs response in that way. Although we did not address this issue 
here, the results obtained with simultaneous blocking of TLR2 
and TLR4 indicated that other receptors are involved as well. This 
presumption could also be supported by the finding that ES L1 
did not affect DC differentiation, while exerted an impact on DCs 
maturation. The possible explanation for this phenomenon could 
be that completely differentiated DCs express different surface 
molecules compared to monocytes, including DC-SIGN, which 
could be important for the ES L1 impact on DCs. These findings 
open the possibilities for future research in trying to understand 
the mechanisms by which ES L1 induce toloregenic DCs.
In conclusion, this study revealed that the treatment of 
human monocyte-derived DCs with T. spiralis ES L1 antigens 
could be a promising new strategy for the development of stable 
tolerogenic DCs, with an increased capacity to suppress the 
inflammatory immune response while favoring the expansion 
of highly potent IL-10- and TGF-β- producing Tregs. Bearing in 
16
Ilic et al. Trichinella-Induced Tolerogenic Human DCs
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 11
mind that the major scientific efforts are made to develop cell-
based therapies that promote tolerance in humans, and although 
more investigation on mechanisms underlying the induction of 
tolerogenic DCs by ES L1 are needed, those tolerogenic DCs 
may present a potentially new tool for the treatment of inflam-
matory disorders.
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